BIRMINGHAM, Ala., May 8 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced it will be exhibiting its VAP Cholesterol Test in booth No. 2123 at the American College of Physicians (ACP) Internal Medicine 2008, the premier scientific meeting for internal medicine. The annual meeting takes place May 13-17, 2008, at the Washington Convention Center in Washington, D.C.
People with a family history or an existing condition of diabetes, high blood pressure or heart disease -- or who are already taking cholesterol lowering medication -- are candidates for the comprehensive VAP (Vertical Auto Profile) Test. In addition, those who didn't score within the desirable ranges of the standard cholesterol test (i.e. those with Triglycerides > 150, HDL < 40, LDL >130, Total Cholesterol > 200) should also opt for the more detailed VAP Test.
The VAP(R) Cholesterol Test (Atherotech, Inc.) is the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the recent expert consensus guidelines from the American Diabetes Association and American College of Cardiology.
Atherotech representatives will be available to discuss the VAP expanded cholesterol test in booth No. 2123, and blood draws will be provided to qualified attendees. Test results will be returned via mail after the conference.
The VAP Test is the most accurate and comprehensive cholesterol test available today, measuring 15 separate components of blood cholesterol as opposed to three in a standard test. The comprehensive test can identify more than twice the number of lipid abnormalities (the No. 1 risk factor of heart disease) than the standard cholesterol test, and is the only cholesterol test to identify markers for Metabolic Syndrome, a precursor for diabetes.
The VAP Test is available nationwide. For more information call 877.901.8510 or visit http://www.thevaptest.com.
About Atherotech, Inc.
Atherotech is a cardio-diagnostic company focusing on direct measurement of the comprehensive lipid panel using the company's patented VAP Technology. The VAP Test directly measures the cholesterol content of all lipids, components and subclasses. It is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations calling for more accurate, direct low-density lipoprotein (LDL) measurement, which is unaffected by triglycerides. The VAP Cholesterol Test -- the new standard of care for patients at risk for cardiovascular disease -- is available through national and regional diagnostic laboratories and is reimbursed by most payers as well as Medicare. For more information, visit http://www.thevaptest.com.
CONTACT: Dan Snyders of Armada Medical Marketing, +1-303-623-1190, ext.
230, dan@armadamedical.com, for Atherotech, Inc.; or Scott Rezek of
Atherotech, Inc., +1-205-314-7412, srezek@atherotech.com
Web site: http://www.thevaptest.com/